Clinical Trial Update: Open-Label Safety Extension Study of Avonex [Phase 4]

View source ↗

Summary

Open-label safety extension study of Avonex (interferon beta-1a) for multiple sclerosis has completed its Phase 4 safety extension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED